SN

Smith & Nephew PLC

SN.LSE smith-nephew.com + Research + Basket
ISIN GB0009223206
Employees 17,000
Phone 44 1923 477 100
Fiscal year end December
IPO Nov 16, 1999
Address Building 5, Watford, United Kingdom, WD18 8YE
11.08
-0.14 (-1.20%)
GBP · LSE
52-week range
9.79
13.89
Trading at 31% of the 52-week range
Market Cap
9.27B
P/E Ratio
20.14
Forward P/E
12.12
Book Value
4.54
Div. Yield
3.54%
% Institutions
74.40%
% Insiders
0.239%

1 Year

-16.8%

3 Year

+30.1%

10 Year

+20.8%
Description

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Actions

Add an action for SN.LSE, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Deepak S. Nath Ph.D. CEO & Director 1972
Mr. Pierre Palassian Interim CFO, Senior VP of Finance & Group Controller NA
Mr. Paul Connolly President of Global Operations 1968
Emily Heaven Head of Investor Relations NA
Ms. Helen Barraclough Group General Counsel & Company Secretary 1979
Ms. Alison Parkes Chief Compliance Officer & Compliance APAC 1972
Mr. Charles Reynolds Head of Corporate Communication NA
Dr. Ajay Dhankhar Ph.D. Chief Corporate Development & Strategy Officer 1971
Ms. Elga Lohler Chief Human Resources Officer 1968
Dr. Vasant Padmanabhan Ph.D. President Research & Development, ENT and Emerging Markets 1967

Financial Highlights

▼
Market Cap: $9.27B
EBITDA: $1.38B
P/E Ratio: $20.14
PEG Ratio: $1.16
Book Value: $4.54
Dividend/Share: $0.40
Dividend Yield: 3.54%
Earnings/Share: $0.55
Profit Margin: 10.08%
Operating Margin: 14.47%
ROA (TTM): 5.16%
ROE (TTM): 11.85%
Revenue (TTM): $6.30B
Revenue/Share (TTM): $7.37
Earnings Growth (YOY): 5.70%
Revenue Growth (YOY): 4.60%

Valuation Metrics

Enterprise Value: $11.66B
Trailing P/E: 20.14
Forward P/E: 12.12

Shares Statistics

Shares Outstanding: 837.03M
Shares Float: 842.65M
% Insiders: 0.239%
% Institutions: 74.40%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$6.16B
Cost of Goods Sold
adjust
$-2.01B
Gross Profit
subtotal
$4.28B
SG&A
adjust
$-2.79B
R&D
adjust
$-302.21M
Other Operating Expense
adjust
$-163.70M
Operating Income
subtotal
$1.02B
Other / Non-Operating Items
adjust
$-399.04M
Net Income
subtotal
$625.00M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SN.LSE!